40 Stocks Just Made New 52-Week Lows
As of Tuesday, October 6, there are 40 US and Canada-listed stocks in the Trefis coverage universe trading at their 52-week lows. The screen only considers companies with a market value above $500 million.
At about $62.0 billion in market value, Boston Scientific (BSX) is the largest company on the list; its stock is down 11.7% over the past month and down 56.6% over the past year. For context, the S&P 500 is up 1.4% over the past month, including dividends.
The Complete 52-Week-Low List
Here are all 40 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D Return |
1W Return |
1M Return |
1Y Return |
|---|---|---|---|---|---|
| BSX | $62.0 Bil | -0.5% | -3.9% | -11.7% | -56.6% |
| CPRT | $24.9 Bil | -3.0% | -1.2% | -20.5% | -40.5% |
| CG | $13.9 Bil | -1.1% | -2.0% | -17.2% | -37.0% |
| TXT | $13.1 Bil | -0.3% | -2.7% | -4.5% | -13.0% |
| TU | $12.4 Bil | 0.0% | -3.4% | -17.3% | -45.3% |
| WSO | $11.1 Bil | -0.5% | -3.3% | -7.7% | -27.6% |
| SARO | $6.8 Bil | -0.5% | -3.7% | -15.6% | -21.3% |
| POOL | $5.7 Bil | -0.7% | -2.6% | -14.6% | -47.6% |
| CPB | $5.7 Bil | -1.6% | -4.9% | -10.0% | -36.7% |
| JOBY | $5.6 Bil | 0.0% | -3.5% | -14.2% | -68.3% |
| TTD | $5.6 Bil | -0.5% | -1.1% | -17.4% | -76.9% |
| EPRT | $5.5 Bil | -0.2% | -1.4% | -12.6% | -10.6% |
| STWD | $4.7 Bil | -0.4% | -6.8% | -16.8% | -25.2% |
| CIGI | $4.5 Bil | -1.6% | -2.7% | -11.5% | -43.5% |
| OTF | $4.3 Bil | -0.8% | -5.6% | -14.4% | -24.9% |
| ACAD | $3.4 Bil | -1.8% | -2.4% | -29.6% | -9.4% |
| ABG | $3.1 Bil | -1.2% | -2.4% | -21.9% | -33.0% |
| CALM | $3.0 Bil | -2.4% | -7.5% | -15.0% | -29.5% |
| MIAX | $2.9 Bil | -10.3% | -9.1% | -27.4% | -26.8% |
| GPI | $2.8 Bil | -1.9% | -1.6% | -21.2% | -46.7% |
| GPK | $2.6 Bil | 0.0% | -6.5% | -16.5% | -53.7% |
| OPEN | $2.2 Bil | -1.7% | -4.2% | -27.9% | -72.0% |
| MLYS | $1.9 Bil | -5.8% | -10.3% | -22.2% | -42.3% |
| XRAY | $1.7 Bil | -0.5% | -5.1% | -25.1% | -34.5% |
| HUBG | $1.7 Bil | -2.0% | -6.9% | -22.9% | -16.4% |
| JBLU | $1.5 Bil | -0.7% | -5.8% | -13.0% | -16.6% |
| GT | $1.3 Bil | -0.4% | -6.8% | -25.4% | -39.6% |
| BBAI | $1.2 Bil | -1.1% | -2.6% | -11.6% | -64.1% |
| PSEC | $0.9 Bil | -5.2% | -13.7% | -16.6% | -20.0% |
| DFH | $0.9 Bil | -1.4% | -11.5% | -29.4% | -63.1% |
| ARDX | $0.8 Bil | -2.4% | -2.4% | -12.4% | -37.1% |
| MFA | $0.8 Bil | -1.0% | -4.5% | -14.6% | -7.1% |
| PCT | $0.7 Bil | -2.1% | -9.6% | -37.3% | -70.5% |
| AVBP | $0.7 Bil | -47.0% | -48.9% | -51.2% | -23.9% |
| WGO | $0.7 Bil | -0.2% | -6.4% | -18.6% | -25.2% |
| BCSF | $0.7 Bil | -0.7% | -3.7% | -5.0% | -10.7% |
| MFIC | $0.7 Bil | -0.1% | -4.1% | -8.7% | -18.5% |
| SLRC | $0.6 Bil | -0.1% | -2.4% | -6.7% | -15.1% |
| CTMX | $0.6 Bil | -0.8% | -6.9% | -31.0% | -22.4% |
| NCDL | $0.5 Bil | -0.4% | -3.5% | -10.0% | -11.8% |
Damaged Businesses Or Marked-Down Prices?
Boston Scientific (BSX) trades at 16.9 times trailing earnings, grew revenue 13.5% over the last twelve months and offers a free cash flow yield of 2.9%.
Copart (CPRT) trades at 16.7 times trailing earnings, grew revenue 0.4% over the last twelve months and offers a free cash flow yield of 5.1%.
Across the list, one-month moves range from -51.2% for ArriVent BioPharma (AVBP) to -4.5% for Textron (TXT).
Over the past year, the median name here is down 31.2%.
3 of the 40 names are also S&P 500 members.
If any of these names tempt you, resist buying on price alone. Our Buy the Dip screen asks the follow-up question that matters: which marked-down stocks still have the growth and cash generation to recover.
Catching Falling Prices Is A Skill. Not Needing To Is A Strategy
Buying stocks at 52-week lows works brilliantly on the survivors and painfully on the rest, and nobody rings a bell to tell you which is which. The honest answer for most investors is to stop needing that call.
The Trefis High Quality (HQ) Portfolio holds roughly 30 businesses selected for the traits that make recoveries likely in the first place: consistent cash generation, strong margins, resilient balance sheets. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Watch the low list for information; let a disciplined basket do the buying.